We can often see such a phenomenon in clinical work, are the same as patients with advanced lung cancer, the results of treatment are very d
We can often see such a phenomenon in clinical work, are the same as patients with advanced lung cancer, the results of treatment are very different. In the past, we can not explain the phenomenon of clinicians, some relatively young patients and quality of life score is relatively good condition, after treatment, but no good results. In recent years, we give a patient in need of treatment in the treatment plan, the heart often have a thought in prayer: I wish I could see to the patient's treatment effect, the patient may not accompany treatment in the ranks, because when we already know the "individual differences". In recent years, with the continuous progress of medicine, the genomic era of cancer research has come, which brings challenges and opportunities to every clinician.
As the American Society of Clinical Oncology (ASCO) chairman George Slec (George Sledge) professor said at this year's ASCO conference, large-scale genome sequencing will soon change our understanding of the biological behavior of the tumor, the new therapeutic targets and reveal the past Difficult miscellaneous diseases help unravel the mystery of resistance. He even thought, from now on, not how many years, one patient went into the clinic and then handed a doctor carrying gigabytes of personal genome data memory stick (Memory Stick), which is how the situation!
Since entering the era of molecular targeting, individualized treatment is extremely important, individual treatment is a bright spot different from group therapy. For each patient, individualized treatment should be based on changes in the patient's genetic or biological behavior. In the treatment of patients, regardless of the choice of target or chemotherapy drugs, we must consider whether the patient has a genetic mutation, the sensitivity of certain enzymes, etc.. Is not all patients are suitable for personalized treatment, but also depends on the further genetic secrets to understand the gene profile of each patient, polymorphism, etc..
Molecular targeted therapy is completely different from chemotherapy. We now come to realize that the development of tumors is a pathway, signal transduction to the cell or DNA, the cells will continue to reproduce, resulting in the formation of tumors. There are many enzymes in this pathway, there are a lot of atrioventricular node, this point is the molecular target of target, as long as can block a certain point, messy conduction disorder was broken, so the tumor may no longer growth. Molecular targeted drugs interfere with or replace or block the enzyme or node on the conduction pathway, thereby interrupting the pathway.
The study of cancer drugs is growing rapidly, especially after the emergence of molecular targeted therapy, drug research focus on molecular targeted therapy, because this is a very efficient method, individualized treatment. This year, next year will continue to have some molecular targeted therapy drugs, on the contrary, the recent research of chemotherapy drugs is relatively backward, but the molecular targeted therapy will replace the chemotherapy drugs, remains to be further study. Molecular targeted therapy and chemotherapy is currently popular, because the role of the two different mechanisms, the former is the pathway, which is directly on the DNA, hope two can be the perfect combination, to significantly prolong the survival of patients is very promising.